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Full-length retroviral RNA serves as both messenger and genomic RNA. Therefore, an unspliced RNA could play both roles:
viral mRNA could be bound in cis by the same Gag polyprotein that it produced, becoming a packaged genomic RNA. To test
this possibility, we used in vivo packaging experiments which coexpressed wild-type NL4-3 RNA and NL4-3-based mutant
RNA that, ideally, could not translate Gag. However, mutating the gag initiator produced a mutant (pNLX) that expressed a
truncated Gag, Gag*, initiated at methionine 10 in the CA region (142 of Pr55Gag). Gag* can be rescued into virions by Gag
and, as it contains the NC domain, could package RNA in cis. To eliminate NC and the CA dimerization domain, a nonsense
mutation in CA at residue 99 was introduced into pNLX to produce pNLXX, which expresses an RNA that should only be
packaged in trans. Cotransfection packaging experiments revealed that wild-type genomic RNA was packaged at an 8-fold
greater level than NLXX RNA given equal expression of both RNAs. Experiments that varied the relative amounts of these
RNAs in the cell found that the wild-type RNA was encapsidated with a packaging preference (i.e., the relative amount of this
RNA in virions versus cells) of 6- to 13-fold over the NLXX RNA, showing that the NLXX RNA did not efficiently compete with
NL4-3 RNA. These data suggest that the wild-type RNA’s ability to express Pr55Gag and, by inference, actively translate Gag
confers an advantage in packaging over the nearly identical NLXX RNA. In contrast, the NLX RNA competed with wild-type
RNA at a 1-to-3 preference. This ratio is similar to the amounts of Gag* rescued by Gag, suggesting that the presence of Gag*ta link t
g proteiINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) full-
length (unspliced) RNA is less than 1% of the total mRNA
in an infected cell (Berkowitz et al., 1996; Swanstrom and
Wills, 1997), yet it is almost exclusively packaged into
virions even in a gross excess of cellular mRNAs. One
clear requirement for specific packaging is the se-
quences in the 5 untranslated region that make up the
packaging signal, psi, which interacts with the nucleo-
capsid (NC) domain of the Gag polyprotein (reviewed in
Berkowitz et al., 1996; Rein, 1994). Experimental and
structural studies suggest that psi is recognized by Gag
through a combination of specific sequences and sec-
ondary structures in the RNA (Amarasinghe et al., 2000,
and references therein). Mutational analyses of the NC
domain of the HIV-1 Gag polyprotein have demonstrated
that both the basic residues and the zinc fingers are
required for specific packaging (Gorelick et al., 1990,
1993; Poon et al., 1996, 1998). While there is a large body
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368of genetic, molecular, and structural data establishing
that both RNA and protein elements are required for
genomic RNA packaging, how and where this recogni-
tion and assembly process occurs are unclear.
Like all retroviruses, the HIV-1 unspliced RNA is both
the messenger RNA that produces Gag and Gag-Pol
polyproteins and the genomic RNA that is packaged into
the virion (Swanstrom and Wills, 1997). During Gag trans-
lation, the full-length RNA that is producing Gag could be
encapsidated by the nascent Pr55Gag. In this way, pack-
aging could occur in cis; i.e., the Gag produced from the
viral mRNA encapsidates it in a first-order fashion. Alter-
natively, the full-length RNA could be separated into two
pools, one functioning solely as an mRNA that produces
viral proteins and another that serves as the genomic
RNA, awaiting encapsidation by Gag. In this model,
translation and packaging are not linked as they occur in
trans: the RNA and Gag must be brought together in a
second-order fashion. The cis packaging model predicts
that a full-length RNA that translates Gag would be
packaged more efficiently than one that does not ex-
press Gag. However, if packaging is solely a trans effect,
then packaging of RNAs should be dependent on the
RNA concentration within the cell and be independent of
cis protein expression.assists in the encapsidation of NLX RNA. Together, our da
RNA and support a model of cis packaging where nascent Ga
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Some of our previous work has found that proteins
associated with translation (e.g., actin and elongationon
factor-1 ) are incorporated into virions (Ott et al., 2000),
suggesting that virions might assemble near translation-
ally active RNA. This led us to examine whether transla-
tion and packaging are linked using in vivo packaging
experiments between wild-type RNA and full-length mu-
tants that do not express Pr55Gag. Analyses of the result-
ant particle-associated RNA revealed that, while the mu-
tant RNA was encapsidated, wild-type RNA was prefer-
entially packaged, even in the presence of excess
competitor RNA. These results show that Pr55Gag trans-
lation contributes to packaging of viral RNAs and sug-
gest that full-length mRNA can be packaged in cis by the
same Gag it expresses.
RESULTS
To determine whether the translation of Pr55Gag affects
packaging, we designed a construct that should produce
an RNA that does not express Gag to be cotransfected
with wild-type. If cis packaging occurs, then the wild-type
RNA should be packaged preferentially over the mutant.
Packaging in trans predicts no preference and that viral
RNAs should be packaged in proportion to their relative
abundance in the cell. To make an RNA that did not
express Gag, minimal changes were made to the pNL4-3
molecular clone of HIV-1 to reduce the chance of intro-
ducing mutations in the RNA that would affect its export,
stability, or packaging. We constructed a full-length com-
petitor plasmid, pNLX, with a six-nucleotide mutation that
produces an amber nonsense codon (TAG) in place of
the gag initiation codon and creates a novel XbaI restric-
tion site as a marker for the mutant RNA (Fig. 1). Theo-
retically, this alteration of gag should eliminate Gag pro-
duction. However, Lee and Linial (1994) have previously
shown that a deletion in gag, encompassing the initiator
codon, produced a truncated Gag that was initiated at an
internal methionine within the capsid (CA) region (resi-
due 10 in CA or 142 of Pr55Gag). Since this truncated Gag
contains the CA dimerization and NC domains, the pNLX
construct also might produce an N-terminally truncated
Gag protein that would bind to RNA and form particles.
To create a competitor that could not encode these
regions, a nonsense mutation within CA (residue 109,
residue 241 of Pr55Gag) that eliminates the potential ex-
pression of NC was introduced into the NLX construct to
produce pNLXX (Fig. 1).
Protein analysis
Viral preparations produced from 293T transfections of
pNL4-3, pNLX, or pNLXX were examined by p24CA immu-
noblot analysis (Fig. 2). Since the N-terminally truncated
Gag proteins potentially produced by pNLX and pNLXX
are not expected to produce virions, five times more virus
preparation (based on original supernatant volume) from
the mutant samples was examined than from the wild-
type in this blot. As expected, no Gag was detected in the
mutant samples, while the wild-type sample clearly con-
tained Gag proteins. Antigen capture assays of the trans-
fection culture supernatants detected little or no p24CA in
the pNLX or pNLXX transfection supernatants (data not
shown). Additionally, the supernatants from these mu-
tants did not contain infectious virus by the HCLZ single-
round infection assay (based on Tat complementation of
a lacZ indicator) or H9 viral replication assays (data not
FIG. 1.Mutant constructs. The constructs used are presented under the corresponding regions of Gag with the nucleotide changes underlined and
pertinent restriction sites displayed. Nonsense codons introduced into pNL4-3 are indicated by an X on the line drawings of the mutants. The Gag
initiator is denoted by an arrow and the Gag* initiator is indicated by a double arrow. The FLAG epitope sequence introduced into NLX is presented
in underlined, single-letter amino acid code under the NLX-FLAG map.
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shown). Together, these results show that mutant parti-
cles were not released into the medium.
Since the mutants did not produce virus, lysates of the
transfected cells were examined by p24CA immunoblot
analysis. The results revealed that the sample of the
NLX-transfected cell lysate produced a band that mi-
grated at an apparently lower molecular weight than the
wild-type p24CA band (Fig. 2) as well as a higher migrat-
ing band at 40-kDa. This latter band is similar to the size
for the truncated Gag reported by Lee and Linial (1994).
Biochemical characterization confirmed that this protein
is a truncated form of Pr55Gag that initiates at amino acid
10 in CA (142 of Pr55Gag), Gag*, and that the lower p24CA
band found in the cell lysates is p24CA-10, the processed
form of the internally initiated polyprotein (manuscript in
preparation). The NLXX cell lysate lane did not contain
any Gag reactive material, possibly due to the inability of
the antiserum to recognize the remaining 99 amino acids
in CA or the stability of this shortened protein inside the
cell.
Gag* is rescued into virions by Gag
Since Gag* lacks matrix (MA), it would be expected to
behave similarly to a myristylation mutant and not bud
from the plasma membrane (Gottlinger et al., 1989). Myri-
stylation-deficient Gag can be rescued into virions by
wild-type Gag (Morikawa et al., 1996). Therefore, Gag*
might be incorporated into particles in our RNA packag-
ing experiments and, if cis packaging occurs, this protein
could incorporate the mutant RNA, obscuring the results.
To determine whether Gag* can be incorporated into
viral particles by Pr55Gag, pNL4-3 and pNLX-FLAG, which
contains a FLAG epitope in CA (Fig. 1), were cotrans-
fected into 293T cells and the proteins produced were
analyzed. The FLAG epitope tag provides a clear and
convenient method of distinguishing wild-type p24CA
from the mutant p24CA-10 processing product, which sep-
arate only slightly by SDS–polyacrylamide gel electro-
phoresis (PAGE) (Fig. 2). Cell and viral lysates from trans-
fections and cotransfections (at an equal molar ratio of
pNL4-3 to pNLX-FLAG) were examined by immunoblot
analysis (Fig. 3). Both virion and cell lysate samples from
the wild-type transfections reacted with the p24CA anti-
serum but not with the FLAG antibody as expected. Viral
preparations from the pNLX-FLAG transfection did not
produce any detectable signal, confirming that Gag*
does not produce particles, while cell lysates reacted
with both p24CA antiserum and FLAG antibody, clearly
showing that Gag* is expressed and processed. Exam-
FIG. 3. Immunoblot analyses of FLAG epitope-tagged mutant. For the
virion blots, 10% of the virus preparation was loaded, while 5% of the
cell lysate was loaded for the cell samples. Samples are identified
above the lanes, and the antiserum used is indicated below each blot.
Viral proteins are identified at the margins of the blots.
FIG. 2. p24CA immunoblot analysis of Gag mutants. Virion and trans-
fected cell samples are identified above each lane and viral proteins
are identified at the margins of the blots. In the virion panel, the lane
containing the NL4-3 sample corresponds to 10% of the virus prepara-
tion while the other lanes contain 50% of the virus preparation. In the
cell lysate, each lane is loaded with approximately 5% of the total cell
lysate isolated from 293T cells transfected with proviral constructs.
Mock samples are material from cells that were transfected with
sheared salmon sperm DNA.
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ination of the virions produced by the cotransfection of
wild-type and pNLX constructs with p24CA and FLAG
immunoblots revealed that both epitope-tagged p24CA-10
and unprocessed 40-kDa Gag*-FLAG were present in
the virion particles. These bands migrated at the same
position in the cell lysate as the Gag* band in the cells
transfected with pNLX-FLAG alone. Together, these re-
sults demonstrate that Gag* can be rescued into virions
by wild-type Gag.
The amount of Gag* incorporated into virions was
examined by microscale reversed-phase high-pressure
liquid chromatography (HPLC), SDS–PAGE gels visual-
ized by Coomassie brilliant blue-staining (C-PAGE), and
protein sequence analysis. To readily distinguish be-
tween the two forms of Gag, active-site mutations in
protease were introduced into both wild-type and mutant
constructs, producing pPRD25A and pNLX/PRD25A, which
express Pr55Gag and Pr40Gag*, respectively. The proteins
in virions produced from an equimolar pPRD25A and pNLX/
PRD25A cotransfection were separated and isolated by
HPLC. C-PAGE and gel densitometry analysis of the Gag
and Gag*-containing fractions revealed that there was
approximately threefold more Pr55Gag than Pr40Gag* in
these virion samples (Fig. 4; and data not shown).
Pr40Gag* was not detectable in the C-PAGE gels of PRD25A
alone, indicating that most of the truncated form was
contributed by the NLX construct in the cotransfected
samples. The amount of Gag* protein rescued into par-
ticles, 25% of wild-type (a 1-to-3 ratio), is important in the
interpretation of the NLX RNA packaging experiments
that follow.
NLXX RNA packages poorly versus wild-type RNA
To determine whether translation of Gag affects the
packaging of RNA, different ratios of wild-type pNL4-3 to
pNLXX were transiently cotransfected into 293T cells.
The RNA in the virions was then analyzed for the relative
amounts of wild-type and mutant viral RNAs by an RNase
protection assay (RPA) using a radiolabeled antisense
probe that can distinguish the mutant from wild-type
genomic RNA by virtue of the six-base mutation at the
gag initiator (Fig. 5A). RNase digestion of 560-nt probe
and wild-type RNA complexes should generate a 386-nt
probe fragment, while those with the NLXX mutant RNA
should produce 339- and 47-nt products due to cleavage
of the probe in the mismatched region. RPA analysis of
RNA isolated from equal amounts of virions, as mea-
sured by p24CA, revealed that the NL4-3 sample con-
tained the 386-nt band expected from the full-length
genomic RNA and no appreciable band corresponding to
the mutant (Fig. 5B). As expected, the NLXX sample
produced no signal, since this construct does not re-
lease virus particles. No 545-nt signal, the size protected
by 5 DNA sequences, was detected in any of the sam-
ples, demonstrating that there was no detectable plas-
mid DNA carried over from the transfection. The RPA of
particle-associated RNA from the 1-to-1 cotransfections
of pNL4-3 and pNLXX showed that the wild-type RNA
was detected while little, if any, of the NLXX RNA band
was visible (Fig. 5B). Increasing the amount of the NLXX
plasmid produced a barely detectable band in the 1:5
and 1:10 cotransfection samples. However, the amount
of wild-type detected was not appreciably decreased.
Since the wild-type RNA was packaged more efficiently
than the pNLXX RNA, even with the latter RNA in excess,
the mutant RNA was not able to efficiently compete with
wild-type RNA for packaging.
The selectivity of RNA packaging in these experiments
was maintained, as the relative amounts of genomic
versus spliced viral RNA were similar for all of the DNA
transfection ratios tested (Fig. 5B). PhosphorImager anal-
FIG. 4. HPLC analysis of virions. Microscale HPLC analyses of
virions produced by cells transfected with PRD25A or cotransfected with
an equimolar amount of PRD25A and NLX/PRD25A are presented. The
chromatograms of the regions containing Gag are displayed with
C-PAGE gels of HPLC fractions aligned underneath. A marker lane (M)
is provided on the left while the protein assignments (made by immu-
noblot and protein sequence analyses) are displayed on the right.
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ysis of the RPA gel found that genomic RNA was pack-
aged in excess over spliced RNA for all of the viral RNA
samples tested: four-, five-, four-, four-, and threefold for
the virions produced from the NL4-3, 1-to-1, 1-to-2, 1-to-5,
and 1-to-10 transfections, respectively. These results are
similar to the fivefold excess of genomic RNA previously
observed in virions (Berkowitz et al., 1995b; Poon et al.,
1998).
Since the RPA results failed to adequately detect the
levels of NLXX RNA, we used an RT-PCR-based assay to
examine the relative amounts of wild-type and mutant
RNA. Cellular and virion-associated RNAs were treated
with RNase-free DNase and then analyzed by RT-PCR in
the presence of trace amounts of radiolabeled nucleo-
tide. A unique XbaI site that was introduced along with
the initiator mutation in pNLXX was used as a marker to
distinguish the mutant from the wild-type PCR product
(Fig. 1). XbaI digestion generates 222- and 115-bp frag-
ments from the mutant PCR products that are readily
distinguishable from the 337-bp DNAs produced from the
wild-type RNA. To ensure that the XbaI digestion of the
viral RT-PCR samples was complete, 1 ng of pNLXX
plasmid DNA (a greater amount of template than would
be produced from samples by RT-PCR) was amplified
and digested. Since the only differences between the
wild-type and the competitor RNAs are the six bases that
lie within the polymerized region, these two templates
amplify with equal efficiency (Fig. 6; data not shown).
RNA samples were PCR amplified (i.e., with no reverse
transcription) to detect potential DNA contamination.
Those RNA samples with no detectable DNA signal were
analyzed by RT-PCR, using a small number of amplifica-
tion cycles to produce linear product to template ratios
(data not shown). Both virion-associated and cellular
RNA samples were examined. RNA preparations from
equal amounts of virions produced by transfection with
either pNL4-3 or pNLXX were analyzed by this RT-PCR
method, generating the expected results: the wild-type
sample produced a 337-bp band, while the lane with the
mutant sample had no bands, since pNLXX does not
produce particles. The plasmid controls produced the
FIG. 6. RT-PCR analysis of wild-type and NLXX competitive packag-
ing. Results of radiolabeled RT-PCR are presented for virion-associated
and cellular RNAs. The samples are labeled above the respective lanes
with the ratio used for cotransfected samples indicated under the
brackets. The wild-type and mutant bands quantitated by PhosphorIm-
ager analysis are labeled by arrows on the right.
FIG. 5. RPA of wild-type and NLXX. (A) The expected sizes for RPA
products generated from the different RNA species and from plasmid
DNA are presented underneath the viral DNA map and the antisense
riboprobe used for analysis. Riboprobe sequences corresponding to
those of the virus are denoted by a thick line while those from the
pGem-3Zf plasmid are indicated by a thin line. (B) Results of the
NL4-3 versus NLXX in vivo competitive packaging are shown. The
samples analyzed are indicated above each lane with the DNA ratios
used for cotransfected samples labeled under the bracket. The posi-
tions of the respective genomic RNAs and RNA size standards are
indicated. The lane containing the undigested probe (Probe) corre-
sponds to 10% of the input riboprobe (8  104 cpm). The lane labeled
tRNA is a negative control to show that the probe is completely
digested under these conditions.
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expected bands. RT-PCR analysis of the RNA samples
from the 1-to-1 wild-type and mutant cotransfection pro-
duced a strong wild-type signal and the clearly fainter
mutant 222- and 115-bp bands after XbaI digestion (Fig.
6). There was a less intense band above the 337-bp
wild-type PCR product. Isolation and PCR amplification
of this upper band produced both bands, suggesting that
this band is a priming artifact of the PCR amplification.
This band was omitted from our packaging calculations.
Results from duplicate samples of virion-associated RNA
produced by cotransfections of pNLXX and wild-type
DNAs were analyzed in three separate experiments to
provide the PhosphorImager data presented in Table 1.
Adjusting for differences in 32P incorporation of the
222-bp NLXX band due to size, there was an average of
eight times more wild-type than mutant RNA in the viri-
ons produced by equimolar cotransfections of wild-type
and pNLXX DNAs (Table 1). RT-PCR analysis of RNA
preparations from these transfected cells showed that,
unlike the RNA in the virion preparations, these samples
contained nearly equal amounts of wild-type and mutant
bands after radiolabel incorporation was adjusted for
(Table 1, Fig. 6). This demonstrates that the steady-state
levels of both RNAs are similar and that the difference
between the wild-type and the mutant RNA packaging
cannot be explained by simple concentration or stability
differences inside the cell. The RT-PCR examination of
virion-associated RNA produced by the cotransfection at
a 1-to-6 ratio of wild-type to mutant showed that the
amount of wild-type versus NLXX RNA packaged in-
creased in comparison to the equimolar transfection
(Table 1, Fig. 6): the ratio of wild-type to mutant RNA
detected in these virions was 2-to-1 despite the excess
of mutant RNA in the cell. Therefore, while a consider-
able excess of NLXX RNA did reduce the relative amount
of wild-type packaging somewhat, it could not overcome
the preference for wild-type RNA. The efficiency of the
wild-type RNAs versus the NLXX RNAs packaged as a
function of the amount of cellular RNA can be measured
by calculating the packaging preference, the relative
amount of wild-type in the virions versus that of the
mutant in the cells. For the equimolar cotransfection, the
packaging preference was 6-to-1 and it increased to
13-to-1 for the excess competitor experiment (Table 1).
Together, these data show that the ability of a genomic
RNA to translate Gag increases its ability to be selec-
tively packaged.
NLX RNA competes with wild-type RNA for packaging
While the NLXX mutant RNA was packaged less effi-
ciently than wild-type RNA, it did have a six-base muta-
tion at the Gag initiator. Computer-assisted RNA model-
ing (data not shown) did not reveal any significant alter-
ation of the stem-loop structures in the psi region,
especially SL3, that appear to be important for packaging
(Berkowitz et al., 1995a; Harrison et al., 1998; McBride
and Panganiban, 1996). However, since the exact se-
quences important for packaging and all of the poten-
tially detrimental mutations to packaging are unknown,
the six-base mutation itself could be the reason for the
inability of the mutant to compete with wild-type. To
address this question, we used the pNLX mutant, since
it contains the same Gag initiator mutation and produces
Gag*, which contains the NC domain and is incorporated
into wild-type particles. If Gag translation affects RNA
packaging in cis, then this RNA should be packaged as
efficiency as wild-type RNA. Additionally, the ratio of the
wild-type RNA to NLX mutant packaged should be sim-
ilar to the 3-to-1 ratio of Gag-to-Gag* found in virions.
However, if the initiator mutation seriously disrupted the
packaging signal, then this RNA would be poorly pack-
aged.
RPA of virion-associated RNA from a cotransfection of
equal amounts of pNL4-3 and pNLX revealed that, unlike
the results with the NLXX RNA presented above, the
mutant RNA was detectable, though present at a smaller
amount than the wild-type RNA. To determine whether
increasing the relative amount of mutant RNA allows it to
be packaged more efficiently, the cotransfection ratio
was changed to increase the relative amounts of NLX
versus wild-type RNA. RPA analysis of the virion-associ-
ated RNA produced under these conditions demon-
strated that the amounts of NLX RNA detected increased
in proportion to the relative amounts of mutant plasmid
cotransfected (Fig. 7). Therefore, unlike our results with
TABLE 1
PhosphorImager Analysis of RT-PCR: NL4-3 and pNLXX Cotransfections
Transfection RNA sample Wild-typea Mutantb WT/mutant WT preferencec
NL4-3:NLXX (1:1) Virions 42,754 5,581 8 6
Cell 84,999 68,914
NL4-3:NLXX (1:6) Virions 23,439 11,216 2 13
Cell 27,194 170,979
a cpm (Avg. 3 experiments) of wild-type band.
b cpm (Avg. 3 experiments) of NLXX band corrected for product length (factor 1.3).
c Genomic RNA packaging preference: WT/mutant ratio adjusted for intracellular RNA ratio ( WT/mutant in virions  mutant/WT in cell).
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the NLXX mutant, the NLX RNA was able to readily
compete with wild-type RNA. Based on signal intensities,
the wild-type and mutant RPA signals would be nearly
equivalent between the 1-to-2 and 1-to-5 ratios (Fig. 7),
indicating that wild-type RNA is packaged approximately
three- or fourfold more than the NLX mutant RNA, similar
to the amount of Gag* incorporated into virions (Fig. 4).
To quantitate and confirm our RPA results, RT-PCR was
performed under the same conditions as the NLXX ex-
periments. The results of PhosphorImager quantitation of
duplicate determinations from two separate experiments
are summarized in Table 2. At the equimolar cotransfec-
tion ratio, the wild-type and NLX mutant RNAs were
detected at a 2-to-1 ratio and a 3-to-1 packaging prefer-
ence after the respective RNA amounts in the cell were
normalized (Fig. 8, Table 2). Analysis of samples from the
other NL4-3-to-NLX ratios showed that the amount of
NLX increased in proportion to its presence in the cell.
As with the NLXX experiments, the relative intracellular
steady-state levels of the RNAs were similar to the
amounts of wild-type and NLX plasmids cotransfected
except at the 1-to-10 ratio (Table 2, Fig. 8). These exper-
iments produced a packaging preference of 3-to-1 for
wild-type RNA in most of the samples. Thus, these re-
sults are considerably different than those obtained for
the NLXX experiments. The ability of the NLX mutant
RNA to compete with wild-type shows that it can be
recognized and packaged. Therefore, the six-base mu-
tation introduced at the gag initiation codon does not
appear to severely affect packaging. While this RNA was
encapsidated in proportion to its cellular abundance, its
packaging preference was approximately threefold less
than wild-type at every cotransfection ratio tested. The
3-to-1 relation between wild-type and mutant RNA pack-
aging mirrors the level of Gag* rescued into virions. This
direct correlation is consistent with a model in which
Gag* is encapsidating its cognate RNA and supports the
a linkage between translation and packaging.
DISCUSSION
Our experiments with wild-type and NLXX indicate that
a viral RNA that can produce Pr55Gag is packaged pref-
erentially over one that cannot. Depending on the relative
amounts of RNA expression there is a 6- to 13-fold
preference for an RNA that can express Pr55Gag. In con-
trast, the NLX mutant RNA that encodes an MA-truncated
form of Gag is encapsidated into virions in the same
proportion as its Gag* translation product (approximately
25% of wild-type), consistent with Gag encapsidating the
same RNA that translated it. These observations suggest
that the presence or absence of the C-terminal region of
Gag is responsible for the ability of NLX RNA and the
inability of NLXX RNA to compete with wild-type for
packaging. While it is unclear what is responsible for this
effect, this region is involved in RNA packaging, Gag
multimerization, and Gag–Pol expression. Additional exper-
iments are under way to better define this phenomenon.
Together, these results support a cis packaging model
in which the newly produced Gag binds the RNA that
FIG. 7. RPA of wild-type and NLX. Results of RPA analysis of the
NL4-3 versus NLX in vivo competitive packaging are shown. The
samples analyzed are indicated above each lane with the DNA ratios
used for cotransfected samples labeled under the bracket. The posi-
tions of the respective genomic RNAs and RNA size standards are
indicated. The lane containing the undigested probe (Probe) corre-
sponds to 10% of the input riboprobe (8  104 cpm). The lane labeled
tRNA is a negative control to show that the probe is completely
digested under these conditions.
TABLE 2
PhosphorImager Analysis of RT-PCR: NL4-3 and pNLX Cotransfections
Transfection RNA source Wild-typea Mutantb WT/mutant ratio WT preferencec
NL4-3:NLX (1:1) Virions 790,447 374,581 2 3
Cell 3,901,595 5,797,942
NL4-3:NLX (1:2) Virions 812,262 572,652 1 4
Cellular 3,069,609 7,035,477
NL4-3:NLX (1:5) Virions 540,515 836,705 0.7 3
Cellular 1,363,332 7,131,792
NL4-3:NLX (1:10) Virions 264,933 713,828 0.4 3
Cellular 1,226,744 9,177,619
a cpm (Avg. 2 experiments) of wild-type band.
b cpm (Avg. 2 experiments) of NLX band corrected for product length (factor 1.3).
c Genomic RNA packaging preference for wild-type RNA: WT/mutant ratio adjusted for intracellular RNA ratio (WT/mutant in virions mutant/WT
in cell).
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produced it. It is possible that this occurs cotranslation-
ally with Gag binding to the rather large 3 untranslated
region of the full-length RNA. Alternatively, the particle
could begin forming around the translating RNA without
binding it directly. Cis encapsidation of viral RNA is
important for HIV-2 genome packaging (Kaye and Lever,
1999) and required for hepatitis B virus genome packag-
ing (Bartenschlager et al., 1990; Hirsch et al., 1990). Since
hepadnaviruses and retroviruses use the same RNA as a
message and as a genome (for the former, RNA is a
precursor that is reverse-transcribed after being pack-
aged into the DNA genome found in the virus), this might
be a general mechanism to promote efficient RNA rec-
ognition during assembly. The linkage of translation,
packaging, and assembly puts all of the required internal
components in close proximity where they can interact.
While we suggest a cis packaging model of genome
encapsidation, it is clear that the psi signal is also im-
portant in RNA recognition. Our results do not conflict
with this model as all of the RNAs, even the NLXX RNA,
were packaged to some degree. Rather, we have exam-
ined how well these RNAs are packaged in the presence
of wild-type. Currently, the mutations within the elements
that are thought to make up psi reduce packaging by a
significant but not absolute amount (a 50–95% reduction)
(Clever and Parslow, 1997; Harrison et al., 1998; McBride
and Panganiban, 1996, 1997). Since viral RNA is a small
portion of the total mRNA population, other factors are
likely to be involved in choosing this low-abundance
RNA. We have previously proposed that factors other
than a psi–NC interaction are important in selectivity
based on results from reciprocal Gag–NC chimeras be-
tween HIV-1 and MMTV (Poon et al., 1998). Gags with
heterologous NC domains still packaged their cognate
RNA (with a mismatched psi) preferentially over a viral
RNA containing the matching psi supplied in trans.
These data are completely consistent with a cis packag-
ing model and are difficult to reconcile with a strictly
trans incorporation mechanism. Efficient psi-indepen-
dent RNA packaging was described by Lee and Linial
(1994) where an RNA with a 5 deletion, encompassing
psi and producing Gag*, was also packaged. Taken
together, our results and these data indicate that, while
psi is important in packaging, cis packaging probably
contributes to RNA recognition. The linkage of transla-
tion to psi-mediated RNA recognition and encapsidation
could work together to provide the remarkable specificity
for retroviral RNAs.
One contradiction to our data is the report of McBride
et al. (1997), who examined packaging of a construct that
terminated Gag expression within CA, eliminating the
C-terminal portion of Pr55Gag. The mutant RNA was effi-
ciently encapsidated and competed with wild-type RNA
for packaging. While there is no clear explanation for this
discrepancy, their mutant should produce MA and a
portion of CA while the MA region is missing from our
NLXX mutant. Our results with the NLX RNA suggest that
the six-base mutation at the Gag initiator of NLXX did not
alter the psi signal, indicating that this is not a likely
reason for these conflicting results. Additional studies
might better explain these differences.
Though we suggest a cis packaging model, trans
packaging certainly occurs. One of the important findings
in retrovirology was the packaging of the many acutely
transforming retroviruses by their corresponding helper
viruses (Vogt, 1997). More recently, retroviral vectors and
packaging systems have been used in research and in
limited clinical applications (Lever et al., 1999; Miller,
1997). These all are examples of packaging in trans, and
they underscore that translation alone does not appear
to be sufficient to account for retroviral packaging; psi is
required. Experiments with translation inhibitors have
shown that translation is not strictly required for pack-
aging (Butsch and Boris-Lawrie, 2000). Richardson et al.
(1993) have demonstrated that HIV-1-expressing cells
FIG. 8. RT-PCR analysis of wild-type and NLX competitive packaging.
Results of radiolabeled RT-PCR are presented for virion-associated and
cellular RNAs. The samples are labeled above the respective lanes
with the ratio used for cotransfected samples indicated under the
brackets. The wild-type and mutant bands quantitated by Phosphor-
Imager analysis are labeled by arrows at right.
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have excess packaging capacity, suggesting that more
Gag is produced than genomic viral RNA. Vectors might
be packaged from this excess Gag. The presence of
excess packaging activity is also suggested by our par-
adoxical finding that the preferential packaging of the
NLXX RNA is reduced as its relative amount within the
cell is increased. This can be explained by the de-
creased amounts of wild-type RNA at the 1-to-6 transfec-
tion ratio, a situation that would limit the amount of
Pr55Gag expressed and thus the packaging capacity of
the cell. Under these conditions, cis packaging of wild-
type RNA should not be affected as packaging and trans-
lation are linked. In contrast, the relative amount of trans
packaging of NLXX RNA would be expected to be de-
pendent on the concentration of Gag. Therefore, its pack-
aging should decrease as Pr55Gag becomes limiting,
which seems to occur in the 1-to-6 cotransfection ratio.
All of these observations are consistent with a model
where Gag is produced in excess and, thus, available to
encapsidate other viral RNAs or simply bud from the cell
without viral RNA.
Based on actinomycin D experiments with MuLV, Levin
and co-workers have suggested that there are two inde-
pendent pools of viral RNA (see Levin and Rosenak,
1976; Messer et al., 1981): one pool acts as message,
while the other acts as the genome that is encapsidated.
Recently, Dorman and Lever (2000) found that actinomy-
cin D did inhibit the production of HIV-1 and HIV-2, while
production of MuLV was not affected. These important
results suggest that HIV-1 and HIV-2 assembly are linked
to translation and are fundamentally different from MuLV.
It is important to note that HIV-2 packaging appears to be
linked more tightly to translation than HIV-1, suggesting
that it is more dependent on a cis packaging mechanism
while HIV-1 appears to support more trans packaging.
Additional translation inhibitor studies have indicated
that full-length HIV RNA is in a single pool, able to be
used as either mRNA or genomic RNA (Butsch and
Boris-Lawrie, 2000).
Our data link the packaging of viral RNA to its ability to
express Gag and, by inference, link the translation of
Gag to packaging. Therefore, HIV-1 virions might begin
to assemble where Gag is translated. Perhaps viral RNA
is transported to the cortical regions of the cell, where it
is translated near the plasma membrane rather than
being transported through the cytoplasm. The first visible
steps of the assembly process by electron microscopy
are at the plasma membrane (Gelderblom, 1991). Addi-
tionally, the pool of Pr55Gag that forms particles is rapidly
associated with membranes after synthesis (Tritel and
Resh, 2000). The placement of Gag and RNA in close
proximity where the virus assembles and buds would
make these processes more efficient than separately
bringing Gag and RNA to the assembly site. RNA trans-
port and spatial translation as a method for protein lo-
calization have been described for several proteins and
are mediated by a zip-code sequence, usually located in
the 3 untranslated region of the RNA (Kislauskis and
Singer, 1992). A plasma membrane proximal model for
viral translation and assembly is consistent with micro-
scopic studies showing that intracellular GFP-labeled
Gag is found mostly as punctuate loci at the cell surface
(Hermida-Matsumoto and Resh, 2000; Sandefur et al.,
2000). Our results provide another, less studied, point of
view for RNA packaging, one that suggests a spatial
organization for RNA recognition and packaging in the
cell. Clearly, additional studies are needed to define and
support this model.
MATERIALS AND METHODS
Plasmids and mutagenesis
The pNL4-3 infectious molecular clone of HIV-1 (Ada-
chi et al., 1987) (GenBank Accession No. m19921) was
used as the parental wild-type in these studies. Oligo-
mediated site-directed mutagenesis by overlap exten-
sion (Horton et al., 1990) was used to generate plasmid
pNLX in which the gag initiation codon (nt 790–793) was
changed to a termination codon and a novel XbaI restric-
tion endonuclease recognition site was introduced. The
six nucleotide changes are shown in Fig. 1. Plasmid
pNLXX was generated by a fill-in reaction of the cleaved
SpeI site (nt 1507) in pNLX with Klenow enzyme to intro-
duce a nonsense amber mutation (TAG) at gag codon
241 (CA codon 109, ACT) within the capsid sequence
(Fig. 1). Plasmid pNLX-FLAG was produced by inserting
the FLAG epitope-coding sequence at nt 1215 in the
plasmid pNLX as described above, by using the mutagenic
oligonucleotide pairs 5-GACTACAAAGACGACGACGA-
CAAAGTACATCAGGCC-ATATCACCTAGA-3 and 5-TTT-
GTCGTCGTCGTCTTTGTAGTCCATTTGCCC-CTGGAGGT-
TCTGCAC-3 (FLAG coding sequences are underlined).
The NL4-3-based protease mutant PRD25A contained a
protease active site mutation (Ott et al., 2000) and NLX/
PRD25A was produced by subcloning the PRD25A mutation
into the NLX plasmid. The entire region subjected to PCR
during the cloning process was DNA sequenced for all of
the mutant viral constructs to ensure that only the de-
sired mutations were produced in these DNAs.
Cell culture methods and immunoblot analysis
Culturing of the transformed human kidney cell line
293T, calcium phosphate transfections, and the prepara-
tion of virions by centrifugation through a 20% sucrose
pad were carried out as previously described (Ott et al.,
1999). Supernatants from transfected 293T cells were
harvested 48 h posttransfection, clarified, and assayed
for p24CA (p24 core profile kit; NEN Life Science Prod-
ucts, Boston, MA) and for RT activity (Gorelick et al.,
1990). The HCLZ (a Tat complementation lacZ assay) or
H9 viral replication assays were performed as previously
described (Gorelick et al., 1990).
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Protein analysis
Immunoblot analysis has been described previously
(Henderson et al., 1988). The blots were probed with
a goat p24CA polyclonal antibody (AVP No. Goat
81#000805) or the mouse FLAG M2 (Sigma Aldrich, St.
Louis, MO) monoclonal antibody and visualized using
Enhanced ChemiLuminescence (Amersham Pharmacia
Biotech, Piscataway, NJ). Microscale reversed-phase
HPLC was carried out on a reversed-phase column as
previously described (Ott et al., 1999) using a 0.1% triflu-
oroacetic acid in acetonitrile (vol/vol) and 0.1% trifluoro-
acetic acid in water (vol/vol) gradient. Changes in the
elution acetonitrile/water gradient program from our pre-
vious conditions are as follows (vol/vol): 10–36% over 11
min, 36–41% over 11 min; 41–46% over 3 min; 46–80%
over 10 min; and 80% for 5 min. Peaks were detected by
UV absorption at 206 and 280 nm and analyzed by
sequencing using a Procise 949 Protein Sequencer
(PE Biosystems Inc., Foster City, CA) and SDS–PAGE as
previously described (Henderson et al., 1987). The ratio
of Pr55Gag to Gag* was determined by densitometer
analysis.
RNase protection assay
Viral RNAs were isolated as previously described
(Poon et al., 1998). Briefly, clarified supernatants corre-
sponding to 200 ng of p24CA were pelleted at 20,000 rpm
for 2 h in an Heraeus HFA 22.1 rotor and were lysed in 4.2
M guanidine thiocyanate, 0.1 M sodium citrate, 0.5% SDS,
7.2% 2-mercaptoethanol. Since mutant constructs do not
release virions, a supernatant volume equivalent to that
of the sample with the lowest p24CA value was used
(typically 1.5 times the wild-type volume). Viral RNAs
were phenol:chloraform:isoamyl alcohol (25:24:1, vol/vol/
vol) extracted, ethanol precipitated, and treated with RQ1
DNase I (Promega, Madison, WI) to remove DNA con-
tamination as previously described (Poon et al., 1996).
RNAs were assayed for the presence of viral genomic
species by an RNase protection assay (Ambion, Inc.,
Austin, TX). To synthesize an antisense riboprobe, plas-
mid pGAN43 was constructed. The AvaI (nt 296)-to-XmnI
(nt 842) 547-bp fragment was inserted into the AvaI-to-
HincII restriction sites of pGem-3Zf (Promega). The
plasmid was linearized with AvaI, and a radiolabeled
probe was produced using [-P32]CTP (NEN Life Science
Products Inc., Boston, MA) and SP6 RNA polymerase
(Ambion, Inc.) according to the manufacturer’s recom-
mended conditions. Viral RNA samples were annealed to
1 ng (8  104 cpm/ng) of the riboprobe. Under these
conditions, the riboprobe RNA is in excess of the viral
RNA in either cell or viral samples. The annealed sam-
ples were digested with RNase provided in the kit, and
equivalent volumes were then subjected to denaturing
8% PAGE.
RT-PCR analysis
RNA was prepared from equivalent amounts of virion
as measured by p24CA assay. Quantitative RT-PCR was
performed on RNA samples as previously described
(Poon et al., 1998). Briefly, RNA samples corresponding to
3 ng of p24CA were reverse-transcribed in a 20-l reac-
tion with Superscript II (Life Technologies, Gaithersburg,
MD), using an antisense gag-specific primer beginning
at nt 1010 (5-CTTTCTGATCCTGTC-3). A third of the
resultant cDNA was subjected to PCR (94°C for 1 min,
42°C for 1 min, 72°C for 1 min, for 18 cycles) with
AmpliTaq DNA polymerase (Perkin–Elmer) in the pres-
ence of [-32P]dATP (NEN Life Science Products), using
the same primer that was used in the RT reaction and
paired with a sense U5-specific primer beginning at nt
673 (5-CAGAGGAGATCTCTC-3). A third of the PCR was
digested with 10 units of XbaI (New England Biolabs,
Beverly, MA) according to the manufacturer’s recommen-
dations and analyzed by 8% PAGE and autoradiography.
A PhosphorImager with ImageQuant software (Molecu-
lar Dynamics, Mountain View, CA) was used to quantitate
the intensity of each band.
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